Tintoré Mar
Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Ps. Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
Neurodegener Dis Manag. 2015;5(6 Suppl):15-7. doi: 10.2217/nmt.15.56.
Spasticity is a prevalent and troublesome symptom for people with multiple sclerosis (MS). Common instruments to measure MS spasticity include the clinician-rated (modified) Ashworth scale and the patient-rated 0-10 spasticity Numerical Rating Scale (NRS). Current opinion is that measurement of MS spasticity should incorporate the patient's perspective. Other instruments to assess spasticity-associated symptoms such as the Penn spasms frequency scale, sleep quality NRS and pain NRS can assist in tracking MS spasticity evolution and inform management choices. Worsening spasticity reduces patient autonomy, impacts negatively on quality of life and increases health resource utilization and costs. Despite the wide range of issues associated with MS spasticity, undertreatment is common and standard treatment options (physiotherapy and classical oral therapies) often fail to provide adequate symptomatic control.
痉挛是多发性硬化症(MS)患者中普遍存在且令人困扰的症状。测量MS痉挛的常用工具包括临床医生评定的(改良)Ashworth量表和患者评定的0-10级痉挛数字评定量表(NRS)。目前的观点认为,MS痉挛的测量应纳入患者的视角。其他评估与痉挛相关症状的工具,如宾夕法尼亚痉挛频率量表、睡眠质量NRS和疼痛NRS,可有助于追踪MS痉挛的演变并为管理决策提供依据。痉挛加重会降低患者的自主性,对生活质量产生负面影响,并增加医疗资源的使用和成本。尽管与MS痉挛相关的问题广泛存在,但治疗不足很常见,标准治疗方案(物理治疗和传统口服疗法)往往无法提供充分的症状控制。